Literature DB >> 27251212

Therapy: Colorectal cancer: how to teach an old drug new tricks.

Axel Grothey1, Lee M Ellis2.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27251212     DOI: 10.1038/nrgastro.2016.87

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  9 in total

1.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

Authors:  Jean-Yves Douillard; Kelly S Oliner; Salvatore Siena; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; Gyorgy Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean Luc Canon; Mark Rother; Richard Williams; Alan Rong; Jeffrey Wiezorek; Roger Sidhu; Scott D Patterson
Journal:  N Engl J Med       Date:  2013-09-12       Impact factor: 91.245

2.  A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

Authors:  Loredana Vecchione; Valentina Gambino; Jonne Raaijmakers; Andreas Schlicker; Arianna Fumagalli; Mariangela Russo; Alberto Villanueva; Evelyne Beerling; Alice Bartolini; David G Mollevi; Nizar El-Murr; Marielle Chiron; Loreley Calvet; Céline Nicolazzi; Cécile Combeau; Christophe Henry; Iris M Simon; Sun Tian; Sjors in 't Veld; Giovanni D'ario; Sara Mainardi; Roderick L Beijersbergen; Cor Lieftink; Sabine Linn; Cornelia Rumpf-Kienzl; Mauro Delorenzi; Lodewyk Wessels; Ramon Salazar; Federica Di Nicolantonio; Alberto Bardelli; Jacco van Rheenen; René H Medema; Sabine Tejpar; René Bernards
Journal:  Cell       Date:  2016-04-07       Impact factor: 41.582

3.  Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

Authors:  Ryan B Corcoran; Chloe E Atreya; Gerald S Falchook; Eunice L Kwak; David P Ryan; Johanna C Bendell; Omid Hamid; Wells A Messersmith; Adil Daud; Razelle Kurzrock; Mariaelena Pierobon; Peng Sun; Elizabeth Cunningham; Shonda Little; Keith Orford; Monica Motwani; Yuchen Bai; Kiran Patel; Alan P Venook; Scott Kopetz
Journal:  J Clin Oncol       Date:  2015-09-21       Impact factor: 44.544

4.  Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.

Authors:  Vlad Popovici; Eva Budinska; Sabine Tejpar; Scott Weinrich; Heather Estrella; Graeme Hodgson; Eric Van Cutsem; Tao Xie; Fred T Bosman; Arnaud D Roth; Mauro Delorenzi
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

5.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

Review 6.  Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.

Authors:  J Randolph Hecht; Jean-Yves Douillard; Lee Schwartzberg; Axel Grothey; Scott Kopetz; Alan Rong; Kelly S Oliner; Roger Sidhu
Journal:  Cancer Treat Rev       Date:  2015-05-21       Impact factor: 12.111

7.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Authors:  Volker Heinemann; Ludwig Fischer von Weikersthal; Thomas Decker; Alexander Kiani; Ursula Vehling-Kaiser; Salah-Eddin Al-Batran; Tobias Heintges; Christian Lerchenmüller; Christoph Kahl; Gernot Seipelt; Frank Kullmann; Martina Stauch; Werner Scheithauer; Jörg Hielscher; Michael Scholz; Sebastian Müller; Hartmut Link; Norbert Niederle; Andreas Rost; Heinz-Gert Höffkes; Markus Moehler; Reinhard U Lindig; Dominik P Modest; Lisa Rossius; Thomas Kirchner; Andreas Jung; Sebastian Stintzing
Journal:  Lancet Oncol       Date:  2014-07-31       Impact factor: 41.316

8.  Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

Authors:  Scott Kopetz; Jayesh Desai; Emily Chan; Joel Randolph Hecht; Peter J O'Dwyer; Dipen Maru; Van Morris; Filip Janku; Arvind Dasari; Woonbook Chung; Jean-Pierre J Issa; Peter Gibbs; Brian James; Garth Powis; Keith B Nolop; Suman Bhattacharya; Leonard Saltz
Journal:  J Clin Oncol       Date:  2015-10-12       Impact factor: 44.544

9.  The consensus molecular subtypes of colorectal cancer.

Authors:  Justin Guinney; Rodrigo Dienstmann; Xin Wang; Aurélien de Reyniès; Andreas Schlicker; Charlotte Soneson; Laetitia Marisa; Paul Roepman; Gift Nyamundanda; Paolo Angelino; Brian M Bot; Jeffrey S Morris; Iris M Simon; Sarah Gerster; Evelyn Fessler; Felipe De Sousa E Melo; Edoardo Missiaglia; Hena Ramay; David Barras; Krisztian Homicsko; Dipen Maru; Ganiraju C Manyam; Bradley Broom; Valerie Boige; Beatriz Perez-Villamil; Ted Laderas; Ramon Salazar; Joe W Gray; Douglas Hanahan; Josep Tabernero; Rene Bernards; Stephen H Friend; Pierre Laurent-Puig; Jan Paul Medema; Anguraj Sadanandam; Lodewyk Wessels; Mauro Delorenzi; Scott Kopetz; Louis Vermeulen; Sabine Tejpar
Journal:  Nat Med       Date:  2015-10-12       Impact factor: 53.440

  9 in total
  1 in total

1.  Colorectal cancer cells require glycogen synthase kinase-3β for sustaining mitosis via translocated promoter region (TPR)-dynein interaction.

Authors:  Firli R P Dewi; Takahiro Domoto; Masaharu Hazawa; Akiko Kobayashi; Takayuki Douwaki; Toshinari Minamoto; Richard W Wong
Journal:  Oncotarget       Date:  2018-01-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.